|
WO2005000194A2
(en)
*
|
2002-10-08 |
2005-01-06 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
|
ZA200502612B
(en)
|
2002-10-08 |
2007-07-25 |
Rinat Neuroscience Corp |
Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
|
|
UA80447C2
(en)
*
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
|
DK2270048T3
(en)
|
2002-12-24 |
2016-01-18 |
Rinat Neuroscience Corp |
Anti-NGF antibodies and methods for their use
|
|
BRPI0407375A
(pt)
|
2003-02-19 |
2006-02-07 |
Rinat Neuroscience Corp |
Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
|
|
AR045056A1
(es)
*
|
2003-07-15 |
2005-10-12 |
Amgen Inc |
Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
ITRM20030601A1
(it)
|
2003-12-24 |
2005-06-25 |
Lay Line Genomics Spa |
Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
|
|
US9396212B2
(en)
|
2004-04-07 |
2016-07-19 |
Visible World, Inc. |
System and method for enhanced video selection
|
|
EP3372614B1
(en)
|
2004-04-07 |
2022-06-08 |
Rinat Neuroscience Corp. |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
|
US7725178B2
(en)
*
|
2004-06-30 |
2010-05-25 |
Cedars-Sinai Medical Center |
Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
|
|
ME00226B
(me)
*
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
|
TWI306862B
(en)
|
2005-01-03 |
2009-03-01 |
Hoffmann La Roche |
Antibodies against il-13 receptor alpha 1 and uses thereof
|
|
EP2298345A3
(en)
|
2005-01-24 |
2012-03-21 |
MedImmune Limited |
Specific binding members for NGF
|
|
ITRM20050290A1
(it)
*
|
2005-06-07 |
2006-12-08 |
Lay Line Genomics Spa |
Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
|
|
BRPI0611901A2
(pt)
|
2005-06-14 |
2012-08-28 |
Amgen, Inc |
composição, liofilizado, kit, e, processo para preparar uma composição
|
|
WO2007016562A2
(en)
*
|
2005-07-29 |
2007-02-08 |
Amgen Inc. |
Formulations that inhibit protein aggregation
|
|
US8008259B2
(en)
|
2005-11-07 |
2011-08-30 |
Copenhagen University, Techtrans Unit |
Neurotrophin-derived peptide sequences
|
|
US7822474B2
(en)
*
|
2005-11-30 |
2010-10-26 |
Cedars-Sinai Medical Center |
Methods for the prediction of arrhythmias and prevention of sudden cardiac death
|
|
CA2667067A1
(en)
*
|
2006-10-19 |
2008-04-24 |
Merck & Co., Inc. |
Antibody antagonists of interleukin-13 receptor .alpha.1
|
|
EP2097447A4
(en)
|
2006-11-15 |
2010-12-29 |
Medarex Inc |
HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
|
|
CA2790018C
(en)
*
|
2006-12-21 |
2015-02-03 |
Amgen Inc. |
Formulations
|
|
US20090075378A1
(en)
*
|
2007-02-20 |
2009-03-19 |
Anaptysbio, Inc. |
Somatic hypermutation systems
|
|
AU2012216653B2
(en)
*
|
2007-08-10 |
2013-12-12 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human nerve growth factor
|
|
MX2010001395A
(es)
*
|
2007-08-10 |
2010-03-10 |
Regeneron Pharma |
Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
|
|
US8309088B2
(en)
|
2007-08-10 |
2012-11-13 |
Regeneron Pharmaceuticals, Inc. |
Method of treating osteoarthritis with an antibody to NGF
|
|
MX2010002249A
(es)
*
|
2007-08-31 |
2010-03-17 |
Amgen Inc |
Formulacion de proteina de estado solido.
|
|
EP2205280B1
(en)
*
|
2007-09-27 |
2019-09-04 |
Amgen Inc. |
Pharmaceutical formulations
|
|
US8796206B2
(en)
|
2007-11-15 |
2014-08-05 |
Amgen Inc. |
Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
|
|
BRPI0822049B1
(pt)
*
|
2007-12-17 |
2021-11-16 |
Pfizer Limited |
Composiqao farmaceutica compreendendo anticorpo antagonista anti-ngf, kit e uso de um anticorpo antingf
|
|
MX2010012031A
(es)
*
|
2008-05-13 |
2011-01-20 |
Novimmune Sa |
Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
|
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
|
BRPI0914916A2
(pt)
*
|
2008-06-30 |
2015-10-20 |
Novo Nordisk As |
anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos
|
|
PT2331090T
(pt)
*
|
2008-09-19 |
2018-02-07 |
Pfizer |
Formulação de anticorpo líquida estável
|
|
WO2010033941A1
(en)
|
2008-09-22 |
2010-03-25 |
Array Biopharma Inc. |
Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
|
|
MY169791A
(en)
|
2008-10-22 |
2019-05-15 |
Array Biopharma Inc |
Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
|
|
JP5752601B2
(ja)
|
2008-12-08 |
2015-07-22 |
ブイエム ファーマ エルエルシー |
タンパク質受容体チロシンキナーゼ阻害薬の組成物
|
|
SG175436A1
(en)
|
2009-05-04 |
2011-12-29 |
Abbott Res Bv |
Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
|
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
WO2011050333A1
(en)
|
2009-10-23 |
2011-04-28 |
Amgen Inc. |
Vial adapter and system
|
|
US10471212B2
(en)
*
|
2009-10-29 |
2019-11-12 |
W. L. Gore & Associates, Inc. |
Silicone free drug delivery devices
|
|
US9597458B2
(en)
|
2009-10-29 |
2017-03-21 |
W. L. Gore & Associates, Inc. |
Fluoropolymer barrier materials for containers
|
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
EP3409289B1
(en)
|
2010-02-26 |
2020-09-30 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
PT3345615T
(pt)
|
2010-03-01 |
2020-01-17 |
Bayer Healthcare Llc |
Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
|
|
AU2011227335B2
(en)
|
2010-03-17 |
2014-11-06 |
Abbott Research B.V. |
Anti-nerve growth factor (NGF) antibody compositions
|
|
ME03376B
(me)
|
2010-05-20 |
2020-01-20 |
Array Biopharma Inc |
Makrociklička jedinjenja kао inhibiтori trk kinaze
|
|
RU2012153786A
(ru)
|
2010-05-28 |
2014-07-10 |
Ново Нордиск А/С |
Стабильные многодозовые композиции, содержащие антитело и консервант
|
|
SG186094A1
(en)
|
2010-06-07 |
2013-01-30 |
Amgen Inc |
Drug delivery device
|
|
WO2012024650A2
(en)
|
2010-08-19 |
2012-02-23 |
Abbott Laboratories |
Anti-ngf antibodies and their use
|
|
US11612697B2
(en)
|
2010-10-29 |
2023-03-28 |
W. L. Gore & Associates, Inc. |
Non-fluoropolymer tie layer and fluoropolymer barrier layer
|
|
US9078878B2
(en)
|
2010-12-01 |
2015-07-14 |
Alderbio Holdings Llc |
Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
|
|
US11214610B2
(en)
|
2010-12-01 |
2022-01-04 |
H. Lundbeck A/S |
High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
|
|
US9539324B2
(en)
|
2010-12-01 |
2017-01-10 |
Alderbio Holdings, Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
|
EP2646468B1
(en)
|
2010-12-01 |
2018-07-25 |
AlderBio Holdings LLC |
Anti-ngf compositions and use thereof
|
|
US9067988B2
(en)
|
2010-12-01 |
2015-06-30 |
Alderbio Holdings Llc |
Methods of preventing or treating pain using anti-NGF antibodies
|
|
US9884909B2
(en)
|
2010-12-01 |
2018-02-06 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
|
AU2012236573B2
(en)
|
2011-03-31 |
2016-06-02 |
Amgen Inc. |
Vial adapter and system
|
|
HUE042822T2
(hu)
|
2011-04-20 |
2019-07-29 |
Amgen Inc |
Automata befecskendezõ szerkezet
|
|
EP2731439A4
(en)
|
2011-07-12 |
2014-12-03 |
Merck Sharp & Dohme |
TRKA KINASE INHIBITORS, COMPOSITIONS AND METHOD THEREFOR
|
|
SI2743348T1
(en)
|
2011-08-11 |
2018-04-30 |
Astellas Pharma Inc. |
Novel anti-human ngf antibody
|
|
PL3045187T3
(pl)
|
2011-10-14 |
2019-09-30 |
Amgen Inc. |
Wstrzykiwacz i sposób montażu
|
|
US8926978B2
(en)
|
2011-10-25 |
2015-01-06 |
Anaptysbio, Inc. |
Antibodies directed against nerve growth factor (NGF)
|
|
WO2013176970A1
(en)
|
2012-05-22 |
2013-11-28 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
|
|
US8945553B2
(en)
*
|
2012-05-22 |
2015-02-03 |
Bristol-Myers Squibb Company |
Bispecific antibodies to IL-23 and IL-17A/F
|
|
CA2875783C
(en)
|
2012-06-06 |
2018-12-11 |
Zoetis Llc |
Caninized anti-ngf antibodies and methods thereof
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
ES2860954T3
(es)
|
2012-11-21 |
2021-10-05 |
Amgen Inc |
Dispositivo de administración de fármacos
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US9127055B2
(en)
|
2013-02-08 |
2015-09-08 |
Astellas Pharma Inc. |
Method of treating pain with anti-human NGF antibody
|
|
JP6135161B2
(ja)
*
|
2013-02-08 |
2017-05-31 |
アステラス製薬株式会社 |
新規抗ヒトｎｇｆ抗体
|
|
JP6336564B2
(ja)
|
2013-03-15 |
2018-06-06 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入器、および自動注入器システム
|
|
TWI614041B
(zh)
|
2013-03-15 |
2018-02-11 |
安美基公司 |
用於注射器之匣盒
|
|
US10646664B2
(en)
|
2013-03-15 |
2020-05-12 |
Amgen Inc. |
Body contour adaptable autoinjector device
|
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
|
WO2014149357A1
(en)
|
2013-03-22 |
2014-09-25 |
Amgen Inc. |
Injector and method of assembly
|
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
EP3041863A4
(en)
|
2013-09-05 |
2017-08-16 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
WO2015039334A1
(en)
|
2013-09-22 |
2015-03-26 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
|
|
WO2015039333A1
(en)
|
2013-09-22 |
2015-03-26 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
|
|
SG11201602876WA
(en)
|
2013-10-24 |
2016-05-30 |
Amgen Inc |
Injector and method of assembly
|
|
CA3168888A1
(en)
|
2013-10-24 |
2015-04-30 |
Amgen Inc. |
Drug delivery system with temperature-sensitive control
|
|
US10519251B2
(en)
|
2013-12-30 |
2019-12-31 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
US10994112B2
(en)
|
2014-02-05 |
2021-05-04 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
|
KR101723997B1
(ko)
|
2014-02-05 |
2017-04-06 |
브이엠 온콜로지 엘엘씨 |
화합물의 조성물 및 이의 용도
|
|
WO2015143652A1
(en)
|
2014-03-26 |
2015-10-01 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
|
|
WO2015143654A1
(en)
|
2014-03-26 |
2015-10-01 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
|
|
WO2015143653A1
(en)
|
2014-03-26 |
2015-10-01 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
|
|
AU2015256082C1
(en)
|
2014-05-07 |
2020-09-10 |
Amgen Inc. |
Autoinjector with shock reducing elements
|
|
US10156562B2
(en)
|
2014-05-16 |
2018-12-18 |
Amgen Inc. |
Assay for detecting Th1 and Th2 cell populations
|
|
CN111840696B
(zh)
|
2014-06-03 |
2022-12-20 |
安姆根有限公司 |
可控制药物递送系统和使用方法
|
|
WO2016035052A1
(en)
*
|
2014-09-05 |
2016-03-10 |
Nvip Pty Ltd |
Anti-nerve growth factor antibodies for treating itching
|
|
EP3206739B1
(en)
|
2014-10-14 |
2021-12-01 |
Amgen Inc. |
Drug injection device with visual and audio indicators
|
|
CN113354649B
(zh)
|
2014-11-16 |
2024-12-10 |
阵列生物制药公司 |
一种新的晶型
|
|
US11357916B2
(en)
|
2014-12-19 |
2022-06-14 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
|
EP3848072A1
(en)
|
2014-12-19 |
2021-07-14 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
CN104910274B
(zh)
*
|
2015-02-12 |
2018-05-04 |
北京华安科创生物技术有限公司 |
抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
|
|
CN104774265B
(zh)
*
|
2015-02-12 |
2018-05-04 |
北京华安科创生物技术有限公司 |
抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
|
|
JP6484345B2
(ja)
|
2015-02-17 |
2019-03-20 |
アムジエン・インコーポレーテツド |
固定及び／または戻りが真空によって支援された薬物送達装置
|
|
WO2016138434A1
(en)
|
2015-02-27 |
2016-09-01 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
|
|
WO2016146730A1
(en)
*
|
2015-03-19 |
2016-09-22 |
Neuheart S.R.L. |
PEPTIDES HAVING TrkA-RECEPTOR-AGONISTIC ACTIVITY OR HAVING NGF-ANTAGONISTIC ACTIVITY
|
|
MA41842A
(fr)
|
2015-03-31 |
2018-02-06 |
Oblique Therapeutics Ab |
Nouveaux procédés de sélection d'épitope
|
|
WO2016161572A1
(en)
|
2015-04-08 |
2016-10-13 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
|
|
WO2016190263A1
(ja)
|
2015-05-22 |
2016-12-01 |
アステラス製薬株式会社 |
新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
|
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
|
WO2017027805A1
(en)
*
|
2015-08-13 |
2017-02-16 |
University Of Massachusetts |
Human antibodies against rabies and uses thereof
|
|
DK3334747T5
(da)
|
2015-08-13 |
2024-10-07 |
Amgen Inc |
Ladet dybdefiltrering af antigenbindende proteiner
|
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
|
EP3368039A1
(en)
|
2015-10-26 |
2018-09-05 |
The Regents of The University of Colorado, A Body Corporate |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
|
JP7082568B2
(ja)
|
2015-12-09 |
2022-06-08 |
アムジエン・インコーポレーテツド |
信号伝達キャップ付き自動注射器
|
|
US11154661B2
(en)
|
2016-01-06 |
2021-10-26 |
Amgen Inc. |
Auto-injector with signaling electronics
|
|
KR20180101479A
(ko)
*
|
2016-01-13 |
2018-09-12 |
젠맵 에이/에스 |
항체 및 그의 약물 접합체를 위한 제제
|
|
RU2757314C2
(ru)
|
2016-01-22 |
2021-10-13 |
Мерк Шарп И Доум Корп. |
Антитела против фактора свертывания xi
|
|
US11421028B2
(en)
|
2016-02-06 |
2022-08-23 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
DK3429663T3
(da)
|
2016-03-15 |
2020-09-28 |
Amgen Inc |
Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
|
|
FI3439662T3
(fi)
|
2016-04-04 |
2024-09-04 |
Loxo Oncology Inc |
(s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
|
AU2017263558B2
(en)
|
2016-05-13 |
2022-12-22 |
Amgen Inc. |
Vial sleeve assembly
|
|
WO2017200989A1
(en)
|
2016-05-16 |
2017-11-23 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
|
EP3458456B1
(en)
|
2016-05-18 |
2020-11-25 |
Loxo Oncology Inc. |
Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
|
|
US11541176B2
(en)
|
2016-06-03 |
2023-01-03 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
|
IL315266A
(en)
|
2016-06-14 |
2024-10-01 |
Merck Sharp ַ& Dohme Llc |
Anti-coagulation factor xi antibodies
|
|
EP3478342B1
(en)
|
2016-07-01 |
2025-03-12 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
|
KR20190077306A
(ko)
|
2016-08-05 |
2019-07-03 |
메디뮨 엘엘씨 |
항-o2 항체 및 이의 용도
|
|
WO2018034784A1
(en)
|
2016-08-17 |
2018-02-22 |
Amgen Inc. |
Drug delivery device with placement detection
|
|
GB201614884D0
(en)
*
|
2016-09-01 |
2016-10-19 |
Oblique Therapeutics Ab |
Method
|
|
GB201617002D0
(en)
|
2016-10-06 |
2016-11-23 |
Oblique Therapeutics Ab |
Multi-protease method
|
|
SG11201903063UA
(en)
|
2016-10-19 |
2019-05-30 |
Medimmune Llc |
Anti-o1 antibodies and uses thereof
|
|
US20200261643A1
(en)
|
2016-10-25 |
2020-08-20 |
Amgen Inc. |
On-body injector
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
GB201621907D0
(en)
*
|
2016-12-21 |
2017-02-01 |
Ucb Biopharma Sprl And Sanofi |
Antibody epitope
|
|
AU2018210301A1
(en)
|
2017-01-17 |
2019-08-01 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
|
WO2018151890A1
(en)
|
2017-02-17 |
2018-08-23 |
Amgen Inc. |
Drug delivery device with sterile fluid flowpath and related method of assembly
|
|
CA3052204A1
(en)
|
2017-02-17 |
2018-08-23 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
|
EP3592403B1
(en)
|
2017-03-06 |
2025-08-20 |
Amgen Inc. |
Drug delivery device with activation prevention feature
|
|
US11571511B2
(en)
|
2017-03-07 |
2023-02-07 |
Amgen Inc. |
Insertion mechanism and method of inserting a needle of a drug delivery device
|
|
AU2018230486B2
(en)
|
2017-03-09 |
2023-05-11 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
|
CA3056011A1
(en)
|
2017-03-14 |
2018-09-20 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
ES3023742T3
(en)
|
2017-03-28 |
2025-06-03 |
Amgen Inc |
Plunger rod and syringe assembly system
|
|
JP7200134B2
(ja)
|
2017-06-08 |
2023-01-06 |
アムジエン・インコーポレーテツド |
トルク駆動式薬物送達デバイス
|
|
US11590294B2
(en)
|
2017-06-08 |
2023-02-28 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
|
JP7195276B2
(ja)
|
2017-06-22 |
2022-12-23 |
アムジエン・インコーポレーテツド |
デバイス起動による衝突／衝撃の低減
|
|
WO2018237225A1
(en)
|
2017-06-23 |
2018-12-27 |
Amgen Inc. |
Electronic drug delivery device comprising a cap activated by a switch assembly
|
|
IL270784B2
(en)
|
2017-07-14 |
2023-11-01 |
Amgen Inc |
Needle insertion-extraction system with a double torsion spring system
|
|
JP7649105B2
(ja)
|
2017-07-21 |
2025-03-19 |
アムジエン・インコーポレーテツド |
薬物容器のためのガス透過性シーリング部材及び組立方法
|
|
US11617837B2
(en)
|
2017-07-25 |
2023-04-04 |
Amgen Inc. |
Drug delivery device with gear module and related method of assembly
|
|
MA49676A
(fr)
|
2017-07-25 |
2020-06-03 |
Amgen Inc |
Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
|
|
MA49838A
(fr)
|
2017-08-09 |
2020-06-17 |
Amgen Inc |
Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
|
|
EP3668567B1
(en)
|
2017-08-18 |
2026-02-18 |
Amgen Inc. |
Wearable injector with sterile adhesive patch
|
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
|
WO2019070472A1
(en)
|
2017-10-04 |
2019-04-11 |
Amgen Inc. |
FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
|
|
ES2971450T3
(es)
|
2017-10-06 |
2024-06-05 |
Amgen Inc |
Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente
|
|
US11464903B2
(en)
|
2017-10-09 |
2022-10-11 |
Amgen Inc. |
Drug delivery device with drive assembly and related method of assembly
|
|
IL273582B2
(en)
|
2017-11-03 |
2024-12-01 |
Amgen Inc |
Systems and approaches for sterilizing a drug delivery device
|
|
EP3706830B1
(en)
|
2017-11-06 |
2024-08-07 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
|
EP3707075A1
(en)
|
2017-11-06 |
2020-09-16 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
|
MA50557A
(fr)
|
2017-11-10 |
2020-09-16 |
Amgen Inc |
Pistons pour dispositifs d'administration de médicament
|
|
JP7370969B2
(ja)
|
2017-11-16 |
2023-10-30 |
アムジエン・インコーポレーテツド |
薬物送達デバイスの扉ラッチ機構
|
|
MX2020005066A
(es)
|
2017-11-16 |
2020-08-20 |
Amgen Inc |
Autoinyector con deteccion de detencion y punto final.
|
|
AR114110A1
(es)
|
2018-02-28 |
2020-07-22 |
Lilly Co Eli |
Anticuerpo anti-trka
|
|
BR112020017701A2
(pt)
|
2018-03-12 |
2020-12-29 |
Zoetis Services Llc |
Anticorpos anti-ngf e métodos dos mesmos
|
|
EP3765516A2
(en)
*
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US12325737B2
(en)
|
2018-03-26 |
2025-06-10 |
Amgen Inc. |
Total afucosylated glycoforms of antibodies produced in cell culture
|
|
CN108623687A
(zh)
|
2018-04-17 |
2018-10-09 |
中山康方生物医药有限公司 |
神经生长因子的单克隆抗体及其编码基因和应用
|
|
EP3788079A4
(en)
|
2018-05-03 |
2022-12-21 |
Shanghai Epimab Biotherapeutics Co., Ltd. |
ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF
|
|
EP3795176A4
(en)
|
2018-05-15 |
2022-01-12 |
Astellas Pharma Inc. |
Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof
|
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
|
MA53375A
(fr)
|
2018-07-24 |
2021-06-02 |
Amgen Inc |
Dispositifs d'administration pour l'administration de médicaments
|
|
CA3103681A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Delivery devices for administering drugs
|
|
US12303677B2
(en)
|
2018-07-24 |
2025-05-20 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
|
CA3103105A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
|
US20210346601A1
(en)
|
2018-09-24 |
2021-11-11 |
Amgen Inc. |
Interventional dosing systems and methods
|
|
CA3110371A1
(en)
|
2018-09-28 |
2020-04-02 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
|
EP3860685A1
(en)
|
2018-10-02 |
2021-08-11 |
Amgen Inc. |
Injection systems for drug delivery with internal force transmission
|
|
US12151089B2
(en)
|
2018-10-05 |
2024-11-26 |
Amgen Inc. |
Drug delivery device having dose indicator
|
|
IT201800009384A1
(it)
|
2018-10-11 |
2020-04-11 |
Cosmo Srl |
Peptide for cosmetic application
|
|
TW202541859A
(zh)
|
2018-10-15 |
2025-11-01 |
美商安進公司 |
具有阻尼機構之藥物遞送裝置及自動注射器
|
|
WO2020081480A1
(en)
|
2018-10-15 |
2020-04-23 |
Amgen Inc. |
Platform assembly process for drug delivery device
|
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
|
EP3873563A1
(en)
|
2018-11-01 |
2021-09-08 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
|
MA54048A
(fr)
|
2018-11-01 |
2022-02-09 |
Amgen Inc |
Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
|
|
AU2020263289B2
(en)
|
2019-04-24 |
2025-05-22 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
|
WO2021041067A2
(en)
|
2019-08-23 |
2021-03-04 |
Amgen Inc. |
Drug delivery device with configurable needle shield engagement components and related methods
|
|
BR112022005583A2
(pt)
|
2019-09-26 |
2022-09-20 |
Amgen Inc |
Métodos para a produção de composições de anticorpos
|
|
CN117186219B
(zh)
*
|
2020-04-17 |
2024-07-12 |
珠海泰诺麦博制药股份有限公司 |
抗人神经生长因子的抗体
|
|
CN113527483B
(zh)
*
|
2020-04-17 |
2023-09-22 |
珠海泰诺麦博制药股份有限公司 |
抗人神经生长因子的抗体
|
|
EP4157881A4
(en)
|
2020-05-27 |
2024-10-09 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
ANTIBODIES THAT SPECIFICALLY RECOGNIZE NERVE GROWTH FACTOR AND THEIR USES
|
|
TW202210467A
(zh)
|
2020-05-28 |
2022-03-16 |
美商美國禮來大藥廠 |
TrkA抑制劑
|
|
EP4159236A4
(en)
|
2020-05-29 |
2024-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing formulation
|
|
US20230273126A1
(en)
|
2020-06-04 |
2023-08-31 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
AU2020204105B2
(en)
*
|
2020-06-19 |
2023-06-08 |
Dartsbio Pharmaceuticals Ltd. |
Anti-human ngf antibodies and methods using same
|
|
US11655292B2
(en)
|
2020-06-23 |
2023-05-23 |
Ampsource Biopharma Shanghai Inc. |
Anti-human NGF antibodies and methods using same
|
|
KR20230087539A
(ko)
|
2020-10-15 |
2023-06-16 |
암젠 인크 |
항체 생산 방법에서의 상대적인 비결합 글리칸
|
|
JP2024523779A
(ja)
|
2021-05-21 |
2024-07-02 |
アムジェン インコーポレイテッド |
薬物容器用の充填レシピを最適化する方法
|
|
EP4352094A1
(en)
|
2021-06-07 |
2024-04-17 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
|
US20250076309A1
(en)
|
2021-10-05 |
2025-03-06 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
CA3240904A1
(en)
*
|
2021-12-16 |
2023-06-22 |
Intervet International B.V. |
Caninized and felinized antibodies to human ngf
|
|
WO2023212586A1
(en)
|
2022-04-27 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods for selecting patients for treatment with an ngf antagonist
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
AU2024256160A1
(en)
|
2023-04-20 |
2025-10-02 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
FR3148027A1
(fr)
*
|
2023-04-24 |
2024-10-25 |
Peptinov |
Composition vaccinale anti-ngf
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2025264860A2
(en)
|
2024-06-18 |
2025-12-26 |
Yale University |
Methods of treating post-covid airway disease
|
|
WO2026030152A1
(en)
|
2024-07-29 |
2026-02-05 |
Amgen Inc. |
System and method for assessing transferability of a fill recipe
|
|
CN121410259B
(zh)
*
|
2025-12-30 |
2026-03-20 |
北京索莱宝科技有限公司 |
用于检测人β-NGF含量的双抗夹心ELISA试剂盒
|